Hematologic Neoplasms: all 1,494 studies
Page 3 of 15. Open to participants first (438), then studies with results posted, then the rest; newest registration first within each.
- A Multi-center Investigation of Family Health.RecruitingNCT06433349
- Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological PatientsRecruitingNCT06422533Not applicable
- Genetics in the Progression of NephropathiesRecruitingNCT06416761
- Characteristics and Outcomes of Patients With Hematological MalignanciesNot yet recruitingNCT06402175
- An Extension Study for Patients Previously Enrolled in Studies With PelabresibRecruitingNCT06401356Phase 3
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 1
- Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical ResearchRecruitingNCT06393335Early Phase 1
- A Clinical Study of HMPL-506 in Patients With Hematological MalignanciesRecruitingNCT06387082Phase 1
- ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)RecruitingNCT06378138Phase 2/3
- Early Detection of Complications During Immunotherapy for Haematological MalignancyRecruitingNCT06377059Not applicable
- Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric AssessmentRecruitingNCT06373471Not applicable
- Early Assessment of Cardiac Function After Treatment With CAR-T CellsRecruitingNCT06350994
- Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)RecruitingNCT06345027Phase 1
- The ACC Preclinical Research Platform for Precision OncologyRecruitingNCT06339541
- CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological MalignanciesRecruitingNCT06326463Phase 1
- DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology ClinicsRecruitingNCT06296368Not applicable
- Physical Therapy in Patients Undergoing Allo-HSCT With cGVHDNot yet recruitingNCT06279585Not applicable
- Early Neutropenic Fever De-escalation of Antibiotics StudyNot yet recruitingNCT06278896Phase 3
- Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical ResearchRecruitingNCT06277011Early Phase 1
- Photobiomodulation for Oral Mucositis and Functional Impairments During Hematopoietic Stem Cell TransplantationRecruitingNCT06260111Not applicable
- Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and MortalityNot yet recruitingNCT06258629
- Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft TransplantationRecruitingNCT06252870Phase 2
- A Clinical Study of SCTC21C in Participants With CD38+ Hematologic MalignanciesRecruitingNCT06252298Phase 1
- European Rare Blood Disorders Platform (ENROL)RecruitingNCT06250595
- Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological TumoursRecruitingNCT06238336Phase 2/3
- Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 BlockadeNot yet recruitingNCT06238245Phase 2
- An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological MalignanciesRecruitingNCT06225856Phase 1
- M-2018-334 in Hematological MalignanciesRecruitingNCT06225050Not applicable
- A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic MalignanciesRecruitingNCT06224855Phase 1
- Is Ibrutinib-related Atrial Fibrillation Dose DependentNot yet recruitingNCT06224452
- Clinical Trial for Non-inferiority and Safety of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Malignancies Who Require Prophylactic Hepatitis B Antiviral TreatmentNot yet recruitingNCT06221657Phase 4
- A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic MalignancyNot yet recruitingNCT06211751Phase 1
- A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular TherapiesEnrolling by invitationNCT06208878
- TGRX-814 Chinese Phase I/II in Patients With Hematological MalignanciesRecruitingNCT06206174Phase 1/2
- Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural EffusionRecruitingNCT06184321Early Phase 1
- Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective DepletionNot yet recruitingNCT06180499Phase 1/2
- Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological MalignanciesRecruitingNCT06150469Not applicable
- Relmacabtagene Autoleucel in Hematologic MalignanciesNot yet recruitingNCT06142188
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a SolutionRecruitingNCT06131801
- IRAF-ABLATION Study: a Multicenter International Retrospective Cohort of Patients With BTK Inhibitors-related AF Treated by Catheter AblationNot yet recruitingNCT06130709
- TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCTRecruitingNCT06125483Not applicable
- IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersRecruitingNCT06119685Phase 1/2
- Immune Profiling for Cancer Immunotherapy ResponseRecruitingNCT06116032
- Weighted Blanket Use to Reduce Anxiety in Oncology PatientsRecruitingNCT06089408Not applicable
- αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)RecruitingNCT06082947Not applicable
- PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUMNot yet recruitingNCT06066255Phase 2
- A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological MalignanciesRecruitingNCT06066203Phase 1/2
- A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological MalignanciesRecruitingNCT06049667Phase 1
- UAB 2419-CD34 Selection Using the Automated CliniMACS ProdigyRecruitingNCT06047886Phase 1
- Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological MalignanciesRecruitingNCT06041815
- Study of VIP943 in Subjects With Advanced CD123+ Hematologic MalignanciesRecruitingNCT06034275Phase 1
- Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT06028828Phase 2
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06001788Phase 1
- Toxoplasma Gondii Infection in Both Children and Adult Patients With Hematological MalignanciesNot yet recruitingNCT05963295Not applicable
- PRO and Wearable Data Insights From Individuals With R/R Multiple MyelomaRecruitingNCT05956457Not applicable
- IVIG for Infection Prevention After CAR-T-Cell TherapyRecruitingNCT05952804Phase 2
- CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCTRecruitingNCT05943067Phase 1/2
- Hypnosis: a Path to AppeasementRecruitingNCT05942885Not applicable
- Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCTRecruitingNCT05921318
- A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesRecruitingNCT05908409Phase 1/2
- AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens)Enrolling by invitationNCT05889806
- "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.RecruitingNCT05888701
- Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological MalignanciesRecruitingNCT05887167Phase 1
- Prospective Validation of the OHI IndexRecruitingNCT05882175
- Discontinuation StudyRecruitingNCT05866757Not applicable
- Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical TransplantRecruitingNCT05849207Phase 1
- First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid TumorsRecruitingNCT05828459Phase 1
- Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot TrialRecruitingNCT05820126Phase 2
- Molecular-genetic Characterization in Patients Undergoing CAR-T Cell InfusionRecruitingNCT05807789
- Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant DiseasesRecruitingNCT05800210Phase 2
- DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating MutationsRecruitingNCT05786716Phase 2/3
- DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.RecruitingNCT05770544Phase 2/3
- DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive CancersRecruitingNCT05770037Phase 2/3
- A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy ProductRecruitingNCT05768269
- DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.RecruitingNCT05768178Phase 2/3
- Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant CyclophosphamideRecruitingNCT05768035Phase 1/2
- Oral Complications in Hematological MalignanciesRecruitingNCT05758207
- Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareRecruitingNCT05745285Not applicable
- Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic MalignanciesRecruitingNCT05739227Early Phase 1
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesRecruitingNCT05735717Phase 2
- Early Detection and Screening of Hematological Malignancies - SANGUINERecruitingNCT05735704
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLRecruitingNCT05735184Phase 1
- The Study of ICP-248 in Patients With Mature B-cell MalignanciesRecruitingNCT05728658Phase 1
- Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or VenetoclaxRecruitingNCT05724121
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingNCT05722886Phase 2/3
- Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell ProductsRecruitingNCT05713214
- A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric PatientsRecruitingNCT05711667Phase 3
- Diet and Cognitive Training in Hematologic Cancer SurvivorsRecruitingNCT05708716Not applicable
- Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced MalignanciesRecruitingNCT05707325Early Phase 1
- Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted TreatmentRecruitingNCT05695638
- Clinical Impact of Thoracic Scanographic Characteristics of Hematologic Malignancy PatientsRecruitingNCT05694806
- Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)RecruitingNCT05692713
- Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic MalignanciesRecruitingNCT05690581Phase 1
- A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMMLRecruitingNCT05690425Phase 1
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or ExtensionRecruitingNCT05678621Phase 2/3
- Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related CancersRecruitingNCT05663502
- Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular TherapyRecruitingNCT05646576Not applicable
- The Optimization of Haploidentical Hematopoietic Stem Cell TransplantationRecruitingNCT05629260
- Switched Memory B-cells as a Marker for Humoral Immune System Recovery in Patients With Secondary Antibody Deficiency Due to Hematological MalignanciesNot yet recruitingNCT05612607Phase 4
- Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment ResistanceNot yet recruitingNCT05602168Not applicable